

OPTIMIZATION OF DENOSUMAB PRESCRIPTION IN OSTEOPOROSIS PATIENTS

C. Salom, F. Bejarano, C. Campabadal, S. Conde, L. Castillo, N. Marco, A. Sanjuan, I. Sacanella, H. Suñer, L. Canadell.

DAP Camp de Tarragona, Hospital Joan XXIII, ICS, Pharmacy, Tarragona, Spain.

Background

Bisphosphonates should be the first choice for osteoporosis treatment, with lower cost and not less benefit than denosumab

Purpose

To evaluate the indication for treatment with denosumab and to develop proposals for optimizing osteoporosis treatment



Material and methods



Cross-sectional study in a primary care area (8 centers)



Data from the ECAP® digital medical record of denosumab-treated patients during January 2020 were reviewed by the Pharmacy Service



Variables: demographic (age and sex), diagnosis, bone mineral density (BMD) and previous fractures, indication, previous treatment and adherence


Results

394 denosumab-treated patients


74.9 ± 9.6 years

92.6%


BMD T-score




Previous fracture




Osteoporosis




Indication



- without a clear indication
- received prior treatment
- adherent



Proposals



A theoretical 75,100 € annual saving

Conclusions

Denosumab should be withdrawn or replaced in 47.1% of patients. The proposals of the clinical pharmacist contribute to safe drug use and health system efficiency. It would be necessary to know the final implementation of the proposals by rheumatologists, which were pending due to the COVID-19 pandemic

Abstract Number: 4CPS-134